Scoggins Christopher J 4

What Happened

• Christopher J. Scoggins, Executive Vice President of Abbott Laboratories (ABT), was granted two awards on February 24, 2026: 18,502 performance-based restricted stock units (awarded shares) and a 76,273-share derivative award (employee stock option). Both items are reported at $0.00 (awarded, not purchased or sold).

Key Details

• Transaction date: 2026-02-24; Filing date: 2026-02-26 (Form 4 accession 0001772286-26-000002).
• Reported price: $0.00 for both the restricted stock award and the derivative award (i.e., grant/award).
• Shares owned after the transaction: not disclosed in the provided filing excerpt.
• Footnote F1: The 18,502 award is a performance-based restricted stock award under Abbott’s 2017 Incentive Stock Program — 3-year term, with no more than 1/3 vesting in any year and vesting tied to achieving a minimum return-on-equity target; the award allows share withholding for taxes.
• Footnote F2: The 76,273 derivative reported is an employee stock option under the same program; it vests/exercises in annual increments of 25,424 on Feb 24, 2027 and 2028, and 25,425 on Feb 24, 2029.
• Timeliness: Filed two days after the transaction date — within the typical two-business-day Form 4 filing window.

Context

• These are compensation awards (an equity grant and an option), not open-market purchases or sales. The option portion is a derivative grant that vests over three years; it has not been exercised or sold as of this filing. Such awards are common executive compensation and do not, by themselves, indicate a buy/sell decision by the insider.